Bayer Virginia, Amaya Beau, Baniewicz Diane, Callahan Colleen, Marsh Lisa, McCoy Asia S
University of Texas MD Anderson Cancer Center.
Memorial Sloan Kettering Cancer Center.
Clin J Oncol Nurs. 2017 Apr 1;21(2 Suppl):13-21. doi: 10.1188/17.CJON.S2.13-21.
BACKGROUND: Significant research progress has been made in immunotherapies since the mid-1990s, and this rapid evolution necessitates evidence-based education on immunotherapies, their pathophysiology, and their toxicities to provide safe, effective care. .
OBJECTIVES: The aim of this article is to provide an evidence-based overview, with implications for practice, of checkpoint inhibitors, monoclonal antibodies, oncolytic viral therapies, and chimeric antigen receptor T-cell therapies. .
METHODS: Each immunotherapy category is presented according to the pathophysiology of its immune modulation, the classes of agents within each category, evidence-based toxicities associated with each class, and implications for practice. .
Immunotherapies vary in their pathophysiology and offer potential to be highly effective for the management of a wide array of cancer types. Understanding the unique pathophysiology and toxicities is necessary to assess, manage, and provide safe, effective patient-focused care.
自20世纪90年代中期以来，免疫疗法取得了重大研究进展，这种快速发展需要对免疫疗法、其病理生理学及其毒性进行循证教育，以提供安全、有效的护理。
本文旨在对检查点抑制剂、单克隆抗体、溶瘤病毒疗法和嵌合抗原受体T细胞疗法进行循证概述，并探讨其对实践的影响。
根据每种免疫疗法的免疫调节病理生理学、各类别内的药物种类、与每类相关的循证毒性以及对实践的影响来介绍每种免疫疗法类别。
免疫疗法的病理生理学各不相同，对多种癌症类型的治疗具有高度有效性的潜力。了解其独特的病理生理学和毒性对于评估、管理以及提供以患者为中心的安全、有效护理至关重要。
